Mike has been a member of the Frazier Life Sciences team since 2006 and brings over 35 years of experience as a scientist and executive to the team. He has co-founded multiple Frazier portfolio companies, including Mavupharma(acquired by AbbVie), Calistoga Pharmaceuticals (acquired by Gilead Sciences), and Stromedix (acquired by Biogen Idec). Mike served as President of Calistoga, which was the first company to demonstrate the clinical benefit of an isoform selective PI3K (idelalisib) inhibitor in hematologic malignancies. That drug, under the brand name Zydelig, received approvals from both the FDA and EMA in 2014 to treat chronic lymphocytic leukemia and follicular lymphoma.
Previously, Mike was one of the founding scientists at ICOS Corporation, where he served as VP and Scientific Director. Mike’s responsibilities at ICOS included discovery, preclinical research, medicinal chemistry, and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Earlier, Mike developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Mike has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry.
Mike is currently a member of the Therapeutic Advisory Board for Frazier company AnaptysBio and the Board of Directors of EpiThany, Inc. He is also a member of the Scientific Advisory Board for Frazier company Lassen Therapeutics as well as OncoResponse. In addition, Mike serves on the Board of Directors for Life Science Washington. He was previously a member of the Executive Committee of the Board of Directors of the Benaroya Research Institute.
Mike received his Ph.D. from the University of Alberta Department of Immunology. His doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms, including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the lab of Irving Weissman, Mike discovered the first cell adhesion molecule implicated in site selective leukocyte traffic.